Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Bruce Bekkar

General OBGYN · ecoAmerica

View

Dr. Andreea Dinicu

General OBGYN · Cleveland Clinic

View

Dr. Catherine Leclair

General OBGYN · OHSU

View

Dr. Luba Soskin

General OBGYN · Bayer (Germany)

View

Dr. Ijeoma Bello

General OBGYN · Essentia Women's Health

View

Dr. Melinda Lukens

General OBGYN · UCMC

View

Dr. Javine Mclaughlin

General OBGYN · Carrot Fertility

View

Dr. Jessica Kingston

General OBGYN · UC

View

Dr. Amaris Yandel

General OBGYN · UPMC Mercy

View

Dr. Marra Francis

General OBGYN · TigerTeamBio

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Trends in Persons Prescribed HIV Postexposure Prophylaxis in the United States, 2015-2023.

    Feb 25, 2026DOI: 10.1093/cid/ciaf581Journal ArticleCID

    Written by: John N LeWeiming ZhuYa-Lin A HuangWei WeiJesse O'SheaLaura M MannMary R TannerAthena P KourtisKaren W Hoover

    Find these authors on Roon

    KH
    Dr. Karen Hoover
    General OBGYN · Baltimore County Department of Health

    Summary

    BACKGROUND: HIV postexposure prophylaxis (PEP) is the only intervention for reducing HIV acquisition risk after exposure. Our objective was to describe PEP user characteristics and analyze national trends in PEP regimens recommended by the Centers for Disease Control and Prevention (CDC) in 2016 and of off-label bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) for PEP.METHODS: We analyzed the IQVIA Real World Data-Longitudinal Prescriptions database to identify persons aged ≥16 years prescribed antiretroviral (ARV) PEP regimens recommended by CDC or BIC/FTC/TAF from 2015 to 2023. We excluded persons with an HIV diagnosis or prescribed ARVs for HIV or hepatitis B virus treatment. Two clinicians reviewed regimens to confirm probable PEP prescriptions. We reported an annual number of PEP users, stratified by demographic characteristics, regimen type, and days of supply.RESULTS: The number of persons prescribed PEP increased from 20 618 in 2015 to 44 934 in 2023. The number of persons prescribed a bictegravir-based PEP regimen increased from 1377 (4.1% of total PEP users) in 2018 to 7536 (16.8%) in 2023. Among 44 934 PEP users in 2023, 53.8% were men, and 39.8% were aged 25-34 years. Most (88.4%) PEP users were prescribed a full course of PEP (28-30-day supply).CONCLUSIONS: Our analysis found an increasing trend in PEP use annually, possibly reflecting greater PEP awareness and broader HIV prevention efforts. Increased use of a bictegravir-based PEP regimen in 2023 suggests a shift in PEP prescribing practices, likely due to its once-daily dosing and high tolerability. Our findings can guide future recommendations for PEP medications.
    KH

    Dr. Karen Hoover

    Obstetrics & Gynecology (OBGYN) · General OBGYN
    Baltimore County Department of Health
    karenhoover